Jan 06, 2017 13:00 pm UTC| Business
Study confirms drug levels for IV BCV 10 mg equivalent to oral BCV 100 mg No gastrointestinal side effects seen with IV BCV at 10 and 25 mg doses DURHAM, N.C., Jan. 06, 2017 -- Chimerix (NASDAQ:CMRX), a...
Jan 06, 2017 13:00 pm UTC| Business
HERNDON, Va., Jan. 06, 2017 -- The Naval Surface Warfare Center Dahlgren Division (NSWCDD) has awarded ManTech International Corporation (Nasdaq:MANT) a prime contract to provide Test and Evaluation (TE) support to its...
Hurco Reports Fourth Quarter and Full Year Results for Fiscal 2016
Jan 06, 2017 13:00 pm UTC| Business
INDIANAPOLIS, Jan. 06, 2017 -- Hurco Companies, Inc. (Nasdaq:HURC) today reported results for the fourth fiscal quarter and fiscal year ended October 31, 2016. Hurco recorded net income of $3,003,000, or $0.45 per...
Neovacs to participate in two upcoming investor events in the United States and France
Jan 06, 2017 13:00 pm UTC| Business
PARIS and BOSTON, Jan. 06, 2017 -- NEOVACS (Alternext Paris:ALNEV), leader in active immunotherapy for the treatment of autoimmune diseases, today announced that Neovacs will participate in two upcoming investor events...
Matinas BioPharma to Present at Biotech Showcase™ 2017
Jan 06, 2017 12:35 pm UTC| Business
BEDMINSTER, N.J., Jan. 06, 2017 -- Matinas BioPharma Holdings, Inc. (OTCQB:MTNB), clinical-stage biopharmaceutical company focused on developing innovative anti-infectives for orphan indications, announced today that...
Avinger Announces Preliminary Fourth Quarter 2016 Results
Jan 06, 2017 12:30 pm UTC| Business
REDWOOD CITY, Calif., Jan. 06, 2017 -- Avinger, Inc. (NASDAQ:AVGR), a leading developer of innovative treatments for peripheral artery disease (“PAD”), today announced that based on preliminary unaudited financial...
Dermira Provides Corporate Update
Jan 06, 2017 12:30 pm UTC| Business
Treatment period for DRM04 ARIDO trial completedPhase 3 acne clinical program for olumacostat glasaretil initiatedTopline data for third and final CIMZIA® (certolizumab pegol) Phase 3 trial expected first quarter of...